Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial ...

A2 Bio shares clinical study progress and the increased diversity of participants in the BASECAMP-1 prescreening study during ...

Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease ...

Flatiron Health today announced their planned presence at the International Society for Pharmacoeconomics and Outcomes Research Europe (ISPOR Europe) 2024 Annual Meeting, including five accepted ...

CHICAGO–(BUSINESS WIRE)–Tempus AI ... were accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th ...

- Ziftomenib combined with ven/aza in R/R NPM1-m or KMT2A-r AML patients selected for poster presentation on Sunday, December 8th - ...

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its ...

Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading ...

U.S. stocks are coasting to the close of their best week in a year with some modest moves on Friday.

Collaboration Revenue: Collaboration revenue generated through the company's collaboration, option, and license agreement with Bristol-Myers Squibb was $0.8 million for the three months ended ...

CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...